All In Biotech

Drug Trial Radar · NCT00639678

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Nov 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Mar 2008

Primary completion

Jul 2008

Study completion Sep 2008

Sponsor

Lead sponsor
Human Genome Sciences Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline; Emergent BioSolutions
First posted
Mar 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of raxibacumab in healthy subjects.

Conditions

  • Healthy

Interventions

  • placeboDrug

    40 mg/kg intravenously, double dose (day 0 and 14), Group 3

  • raxibacumabDrug

    40 mg/kg intravenously, double dose (day 0 and 14), Group 1

  • placeboDrug

    40 mg/kg placebo, single dose (day 0), Group 4

  • raxibacumabDrug

    40 mg/kg intravenously, single dose, day 0, Group 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment PeriodTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  2. Number of Participants With Hematological Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  3. Number of Participants With at Least a 2-grade Worsening From Baseline in Hematological ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  4. Number of Participants With Liver Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  5. Number of Participants With at Least a 2-grade Worsening From Baseline in Liver ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  6. Number of Participants With Electrolyte Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  7. Number of Participants With at Least a 2-grade Worsening From Baseline in Electrolyte ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  8. Number of Participants With Other Chemistry Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  9. Number of Participants With at Least a 2-grade Worsening From Baseline in Other Chemistry ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  10. Number of Participants With Thyroid Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  11. Number of Participants With Urinalysis Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  12. Number of Participants With at Least a 2-grade Worsening From Baseline in Urinalysis ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
  13. Number of Participants Who Developed an Anti-raxibacumab Antibody ResponseTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.